Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
As i mentioned once before I own another company that has partnered Japan only for stroke, as I suggest IPIX should do with ABSSSI, that other co. had a similar mkt cap about a year ago, it now has a MC approaching 3 times IPIX's, primarily due to that partnership. Partnering is the name of the game for public pre-revenue bio in this market climate, so why not partner in a foreign country with a regional player preserving the largest markets. Not so much for revenue but rather to off load the expense of advancing the pipeline.
K, even if given only as an adjuvant, especially if they can perfect an oral form, may be added to boost the immune response in many existing and developing immunotheropies thus yielding higher amounts of antibodies and a longer-lasting protection, lowering the amount of primary drug therapy and thus minimizing the amount of injected foreign material. There truly are many potential combinations making K a potential blockbuster even if only given as an adjuvant..
An ABSSSI trial would not cost a foreign partner $30 mm in India, or China or Korea or any other place on earth. Seems like a waste to let a valuable asset sit idle this long.
Maybe the reason has to do with proprietary IP, but I own stock in a co. who licensed a PIII stroke trial to a Japanese co under generous terms, while gearing up to partner a trial in US and EU under hopefully far better terms. It was far from a perfect hand off but they are finally well under way in Japan.
Anyone peculating why Leo is letting B/Absssi sit on the shelf and not progressing it along via a regional size pharma partner for a limited geographic area like Japan, or Korea or heck even Asia, anything to prove its value by generating results? Even if it's for free with the partner paying all related expenses it's better than letting the competition leap frog us while we sit like an elf on a shelf waiting for Santa Clause. The all or nothing approach seems fraught with issues as far as I'm concerned.
The same could be said for any of our drugs for limited indications I suppose, but B/Absssi is far enough along that I would think a regional player would take a swing at it.
I believe the risk in owning IPIX now is very asymmetric and is worth the risk of building a position twice as large as what I would feel comfortable holding over the long term. At current prices the gain realized from the move up if one or two the current trials are even moderately successful is significantly different from the loss incurred from its move down if they are anything but catastrophically poor. I'm within about 10-15% of my max commitment for any position (except perhaps for short term gov bonds).
I'd expect Aspire to employ a plethora of risk management techniques which would dictate opportunistic selling/trading rather than static or steady selling, but that's just my WAG. It seems obvious to me that SP manipulation occurs do to the purposeful placing of out sized trades during predictably thin but influential trading times like just after the open and just before lunch where larger numbers of interested non professional parties are likely to check the price trend which may influence their opinions. These times may be a good time for bullish investors or swing traders to consider looking for a small discount.
I suspect it depends upon how good the BOM results are. Too many moving parts to speculate on the outcome with much confidence. I'd expect it depends on who the partner is, their size, market breath and reach and risk profile. Most potential partners would at least attempt to execute an options strategy for the franchise but it will come down to what Leo and Co. believe the indication is worth individually and as part of the franchise as compared to the partners estimates of the same, and their ability to afford a larger deal along with the associated risk and how much upfront cash IPIX wants for a franchise deal as opposed to BOM alone. IMO it's impossible to know in advance without more information.
Bugs, I sold 600,000 shares between $3.80 and $4.80 at the last top, so your wasting your time calling me a dreamer. I'm betting that I do significantly better this time. More shares and lower avg cost. We'll see who's laughing at the finish line.
Positive top line results along with a partnership announcement is possible and would cause an immediate tsunami of buying. Difficult to imagine what the peak price might be. Come on Leo, give-um the old one two.
Aspire is obligated to purchase up to 30 million dollars worth of IPIX shares, which at 70 cents would be almost 43,000,000 shares. Theoretically if they wanted to purchase them at lower prices they could easily pressure the SP by selling about 10% of the daily volume each day for three to five months which by some calculus would pay off nicely if IPIX exercises the purchase option before good trial results are released. Of course, the opposite result would happen if IPIX releases great trial results before exercising their option with Aspire. I think it would be a bad bet for Aspire to try to rig the market, but some may think the risk is worth the potential reward. It seems to me that the market for small cap bio has turned negative and each day nervous selling exceeds opportunistic buying by just a little bit so there is a mostly downward steady pressure on the stock. Selling begets selling kind of logic. That's my WAG anyway. Personally I've been adding lately and I'm eager for results.
LBK is spot on here. Anyone who has been around a while and pays attention to stock trading would concur. I believe those who constantly suggest that A RS is in shareholder interest know this, are disingenuous at the least, and are thus much more interested in facilitating a short sale and the SP declining then in it appreciating. "Everyone talks their book" is the equivalent of Colombo saying " follow the money".
OBV is only -12,000 on my chart, hardly overwhelming.
I'm sympathetic to your logic to a point, but it's merely guess work as as there are many platforms that don't play out that way, as well as other MM's with different clients as I'm sure must you know. At least admit it's not in Audra's interest to sell shares at lower prices. It seems to me that the fact you repeatedly allege Aruda is complicit in driving the price down is more a tell of your motive than it's indicative of Aruda's, as it's
obviously antithetical to their interests.
The bid was .71 the ask is .73 and 40k crossed the tape at .72
That's all we know, it could have been initiated by a purchaser or seller and by anyone. I'm personally sympathetic to the opinion that Aspire has incentive to hold the SP down if they believe IPIX will draw on their line before positive results are announced but then again if IPIX demonstrates favorable results and a related partnership before they draw on Aspire's funding then Aspire would be far better holding, and potentially selling at $5 rather than .71 so anyone can speculate, but that's all it is even if you say it every day all day ad nauseam.
If the treatment shows overwhelmingly positive
results, the IRB, or the DSMB can also prematurely stop
the trial and allow all participants to cross
over into the more effective treatment arm
of the trial. It is considered inhumane to keep people on placebo if the trial is safe and overwhelmingly efficacious.
My broker is showing a flat close.
I was under the impression they were fielding questions, is that incorrect?
the fact they are willing to meet with shareholders on the record in a public forum and freely answer questions is a positive in my book, more positive news is always better, but the willingness to honestly answer shareholder questions is a characteristic of confident and great management IMO.
I think just having a partnership for any B indication with BP would help the SP quite a lot and the info garnered from a large expensive study would inform the Co. and FDA about a lot of things. Just my opinion, but with dapto coming off patent I'd think ABSSSI could be a valuable replacement with it's one time application and lack of resistance.
the question that's been nagging me is why no partner for ABSSSI?
in an email response from the Co. they indicated that pharma's interests were "specific". That in itself does not mean much to me as "specific" could mean almost anything, the entire Co., a platform, a drug or a single indication. But its likely fertile soil to sift through in next weeks public conference call.
I'm encouraged that they are doing the call as I don't feel comfortable asking most of the questions I'd like answers to and they wouldn't be able to answer in a private forum anyway. I'm hoping the call will give us the flavor and color we seek.
it seems to me that B OM deserves the Co.'s highest priority. Nothing on the market to compete with, if final P2 results are similar to what we've seen to date the trial should qualify for BTD and would recruit quickly due to simplicity non-invasive delivery method and serious affliction it prevents. I'd sure sign up if I was a candidate. I think BP will be all over this one very soon. The safety profile is actually quite good and substantial if you consider all the trials it's been involved in.
One word answer; PARTNER
enjoyed reading the article Sox, thanks for posting.
Borrowing liberally from the Good Book, let he who has the better resume cast the first stone.
SPEAKS FOR ITSELF
ARTHUR P. BERTOLINO, MD, PHD, MBA
President and Chief Medical Officer
Dr. Bertolino serves as President and Chief Medical Officer at Cellceutix. Dr. Bertolino is a leading pharmaceutical dermatology executive with over 15 years of domestic and global drug development and management experience. Previously, he was Vice President of Dermatology at Novartis, Vice President and Chief Medical Officer of Peplin, Inc., and Senior Director of Dermatology at Pfizer. Dr. Bertolino has authored over 50 abstracts, papers, and book chapters, and has been a regular on-air and in-print contributor to leading media companies. Dr. Bertolino received a BS (Chemistry/Biochemistry) degree from SUNY Stony Brook, an MD and PhD (Pharmacology) from The Johns Hopkins University School of Medicine, and an MBA from the University of Michigan Stephen M. Ross School of Business.
maybe that's true but iv'e not noticed many larger 25k - 40k share trades lately, seems to me that it trades quite differently while trending down then it does going up. This is just my subjective impression and may not be germane.
Trading at 4 decimal places would seem to indicate that it's not retail selling. I'm guilty of beating another dead horse myself, I know, sorry.
Rather than beating the same old drum why don't you simply email investor relations and ask.
I have no idea what those 3 investors in the pipe have in mind for their investment, but I considered that they possibly held shares at a higher prices and wanted to lower their basis. The wash sale rule would prevent them from selling their high priced shares for 30 days so who's the current seller? Same old question same old answer, I dunno. Suspect it's a hedge fund or Aruda or Aspire not wanting to hold thru P results, but at this point guessing seems like pissing into the wind.
I'm realistic enough to see that the share price agrees that you have a valid concern, but nothing happens in a vacuum and all the crap with Aruda, Aspire, Mako, Rosen, AF and other that piled on created fear in the hearts of the retail investors who own this stock. Therefore, as has been said by others smarter then me, "be brave when others are fearful".
I agree that Leo blew a great chance to up-list and raise working capital at 4 or 5 or maybe 6 times (with the up-list) the current share price, but that was years ago and lesson learned. The new team and especially with the addition of Dr. B, IMO has added the expertise to
accomplish the " partnership, a huge milestone payment, a hugely respectable endorsement, a well respected BOD addition, something along these lines to change the course of the stock" that you pointed out.
I think retail investors have a shorter time horizon (in general) and less tolerance for losses than institutional investors who have the means and expertise to look across the valley and confirm the validity of their investment. The long period of steady price erosion precipitated by all the events we have publicly bitched or privately stewed over has brought us to the point that we need a partnership which depends upon the latest series of trials that were designed to answer questions brought up by BP intended to make 2017 the year of partnerships. JMHO.
"Doesn't matter". It certainly does matter in the long term, dilution is permanent, trading existing shares is temporary and easily reversed with material progress in any of the trials, partnerships or sales of an asset such as P. We are much closer to "material progress" according to everything knowable to shareholders.
It seems obvious at this point that we're going to need the type of announcement that will generate a several multi-million share days to clean out the sellers inventory, change their minds or bring in larger investors or institutions who would like to take them out... Plenty of opportunity in the pipeline for this to happen and perhaps quickly. I'm not going to sweat the few cents up or down days as I wait for a material catalyst.
"OC phase 2A could yield some good outcomes"
If positive, this 2A will at the very least inform the design of the next trial and encourage physicians and patients to favorably consider participation in a double blind trial, which is a leap of faith due to the placebo arm, which will be required by the FDA.
The FDA has awarded Kevetrin Orphan Drug status for Ovarian Cancer, Pancreatic Cancer, and Retinoblastoma, qualifying it for developmental incentives and an extra 7 years of market exclusivity upon drug approval. The FDA also has granted Kevetrin Rare Pediatric Disease designation for childhood Retinoblastoma.
"Cellceutix currently is evaluating Kevetrin in an open-label, dose-escalation Phase 2a trial in Platinum-Resistant/Refractory Ovarian Cancer. Patients will receive more frequent dosing (three times per week) at higher starting levels (250 mg/m2) and will be subsequently followed while under standard of care cancer treatment. The estimated primary completion date for the study is December 31, 2017."
https://clinicaltrials.gov/ct2/show/NCT03042702
A Phase 2 Study of Kevetrin in Subjects With Ovarian Cancer
This study is currently recruiting participants. (see Contacts and Locations)
Verified February 2017 by Cellceutix Corporation
Sponsor:
Cellceutix Corporation
Information provided by (Responsible Party):
Cellceutix Corporation
ClinicalTrials.gov Identifier:
NCT03042702
First received: February 1, 2017
Last updated: February 17, 2017
Last verified: February 2017
Yup, P,B and K.
I concur.